Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCR-ABL1 fusion
i
Other names:
BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
25
;
613
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
MRDx BCR-ABL Test (1)
QXDx™ BCR-ABL %IS Kit
Quantidex qPCR BCR-ABL IS Kit
Xpert® BCR-ABL Ultra
MRDx BCR-ABL Test (1)
QXDx™ BCR-ABL %IS Kit
Quantidex qPCR BCR-ABL IS Kit
Xpert® BCR-ABL Ultra
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
nilotinib
Sensitive: A1 - Approval
nilotinib
Sensitive
:
A1
nilotinib
Sensitive: A1 - Approval
nilotinib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
bosutinib
Sensitive: A1 - Approval
bosutinib
Sensitive
:
A1
bosutinib
Sensitive: A1 - Approval
bosutinib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
nilotinib
Sensitive: A2 - Guideline
nilotinib
Sensitive
:
A2
nilotinib
Sensitive: A2 - Guideline
nilotinib
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
bosutinib
Sensitive: A2 - Guideline
bosutinib
Sensitive
:
A2
bosutinib
Sensitive: A2 - Guideline
bosutinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
imatinib
Sensitive: A2 - Guideline
imatinib
Sensitive
:
A2
imatinib
Sensitive: A2 - Guideline
imatinib
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A2 - Guideline
blinatumomab
Sensitive
:
A2
blinatumomab
Sensitive: A2 - Guideline
blinatumomab
Sensitive
:
A2
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
Tyrosine kinase inhibitor
Sensitive
:
A2
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
Tyrosine kinase inhibitor
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
Tyrosine kinase inhibitor
Sensitive
:
A2
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
Tyrosine kinase inhibitor
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
Tyrosine kinase inhibitor
Sensitive
:
A2
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
Tyrosine kinase inhibitor
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
bosutinib
Sensitive: A2 - Guideline
bosutinib
Sensitive
:
A2
bosutinib
Sensitive: A2 - Guideline
bosutinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
nilotinib
Sensitive: A2 - Guideline
nilotinib
Sensitive
:
A2
nilotinib
Sensitive: A2 - Guideline
nilotinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive: A2 - Guideline
ponatinib
Sensitive
:
A2
ponatinib
Sensitive: A2 - Guideline
ponatinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive: A2 - Guideline
brexucabtagene autoleucel
Sensitive
:
A2
brexucabtagene autoleucel
Sensitive: A2 - Guideline
brexucabtagene autoleucel
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
etoposide IV
Sensitive: B - Late Trials
etoposide IV
Sensitive
:
B
etoposide IV
Sensitive: B - Late Trials
etoposide IV
Sensitive
:
B
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
ponatinib
Sensitive: B - Late Trials
ponatinib
Sensitive
:
B
ponatinib
Sensitive: B - Late Trials
ponatinib
Sensitive
:
B
BCR-ABL1 fusion
Acute Myelogenous Leukemia
BCR-ABL1 fusion
Acute Myelogenous Leukemia
asciminib
Sensitive: C1 - Off-label
asciminib
Sensitive
:
C1
asciminib
Sensitive: C1 - Off-label
asciminib
Sensitive
:
C1
BCR-ABL1 fusion
Leukemia
BCR-ABL1 fusion
Leukemia
asciminib
Sensitive: C1 - Off-label
asciminib
Sensitive
:
C1
asciminib
Sensitive: C1 - Off-label
asciminib
Sensitive
:
C1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
bosutinib + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
bosutinib + inotuzumab ozogamicin
Sensitive
:
C2
bosutinib + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
bosutinib + inotuzumab ozogamicin
Sensitive
:
C2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: C2 – Inclusion Criteria
blinatumomab
Sensitive
:
C2
blinatumomab
Sensitive: C2 – Inclusion Criteria
blinatumomab
Sensitive
:
C2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
T-lymphocyte cell therapy
Sensitive
:
C3
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
T-lymphocyte cell therapy
Sensitive
:
C3
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
venetoclax + nilotinib
Sensitive: C3 – Early Trials
venetoclax + nilotinib
Sensitive
:
C3
venetoclax + nilotinib
Sensitive: C3 – Early Trials
venetoclax + nilotinib
Sensitive
:
C3
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
venetoclax + bosutinib
Sensitive: C3 – Early Trials
venetoclax + bosutinib
Sensitive
:
C3
venetoclax + bosutinib
Sensitive: C3 – Early Trials
venetoclax + bosutinib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login